Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer showdown: which drug combo works best?

NCT ID NCT07394062

Knowledge-focused Sponsor: Gazi University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 400 people with advanced non-small cell lung cancer whose tumors have low PD-L1 levels (below 50%). Researchers will compare two standard treatment combos: chemotherapy plus pembrolizumab versus nivolumab plus ipilimumab with chemotherapy. The goal is to see which approach leads to longer survival and better quality of life in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pembrolizumab, nivolumab, ipilimumab, and platinum-based chemotherapy
What this could lead to
If successful, this study could help doctors choose the best treatment for advanced lung cancer patients with low PD-L1 levels, improving survival and quality of life.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient differences. It won't prove one treatment is better, only provide real-world insights.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients with metastatic non-small cell lung cancer and PD-L1 expression below 50% who are receiving standard first-line chemo-immunotherapy regimens in routine clinical practice.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years. * Histologically or cytologically confirmed non-small cell lung cancer. * Metastatic (stage IV) disease at the time of study entry. * Tumor PD-L1 expression \<50%. * Initiation of first-line systemic treatment with either chemotherapy plus pembrolizumab or nivolumab plus ipilimumab in combination with chemotherapy, according to routine clinical practice. * Ability to provide informed consent. Exclusion Criteria: * Prior systemic therapy for metastatic non-small cell lung cancer. * Participation in an interventional clinical trial that mandates treatment assignment. * Presence of another active malignancy requiring systemic treatment. * Inability to comply with routine clinical follow-up or data collection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic nonsmall cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic nonsmall cell lung cancer Nonsmall cell lung cancer, stage IV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ankara Etlik City Hospital

    RECRUITING

    Ankara, Turkey (Türkiye)

  • Gazi University Faculty of Medicine, Department of Medical Oncology

    RECRUITING

    Ankara, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.